How it works
A dual GIP and GLP-1 receptor agonist combining two incretin pathways involved in glucose-dependent signaling and energy-balance regulation.
CATALOG ITEM
Tirzepatide
Certificate of analysis (COA)
- Strength
- 10 mg
- Batch number on the certificate (Batch Number)
- CS-ze10-1020
- Analysis date
Identifying details were hidden for privacy. The test results are shown as they appeared in the original report. For research use only.
Tirzepatide peptide specifications and vial packs
The Tirzepatide research peptide is listed in several vial-pack strengths. The material name, labeled strength, number of vials and certificate of analysis describe different parts of a catalog option; review each when comparing packs.
| Labeled strength | Units per pack |
|---|---|
| 10 mg | 10 vials |
| 15 mg | 10 vials |
| 20 mg | 10 vials |
| 30 mg | 10 vials |
| 45 mg | 10 vials |
| 60 mg | 10 vials |
| 90 mg | 10 vials |
Select a strength above to see its current pack price. These are catalog specifications, not instructions for use.
Reviewing the Tirzepatide COA
The certificate panel above follows the selected strength. Check the material name, strength, batch number and analysis date on the report. A certificate describes the tested sample and batch; it does not establish results for every pack or other batches.
When no certificate is available for the selected strength, the panel says so. The certificate library includes the available reports and a search by product or batch number.
What it is studied in
Studied for obesity, overweight, type 2 diabetes, and metabolic disorders.
Key benefits
Relation to glucose control, satiety, body weight, and metabolic markers.
What sets it apart
Combines two incretin pathways in one molecule, GIP and GLP-1.